Skip to main content
GutCited

Processo di ricerca

477 figure da ricerca revisionata da esperti

Tutti Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 18
Figure 18 Chart

Extended analysis from the berberine autoimmune hepatitis study, examining molecular pathways or additional biomarkers related to gut-liver axis communication and intestinal barrier function.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 19
Figure 19 Chart

Extended analysis from the berberine autoimmune hepatitis study, examining molecular pathways or additional biomarkers related to gut-liver axis communication and intestinal barrier function.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 20
Figure 20 Chart

Extended analysis from the berberine autoimmune hepatitis study, examining molecular pathways or additional biomarkers related to gut-liver axis communication and intestinal barrier function.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 29
Figure 29 Chart

Gut microbiota sequencing or metabolomic data from the berberine-treated autoimmune hepatitis model, characterizing microbial community shifts and their potential functional implications.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 30
Figure 30 Chart

Gut microbiota sequencing or metabolomic data from the berberine-treated autoimmune hepatitis model, characterizing microbial community shifts and their potential functional implications.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 35
Figure 35 Chart

Gut microbiota sequencing or metabolomic data from the berberine-treated autoimmune hepatitis model, characterizing microbial community shifts and their potential functional implications.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 40
Figure 40 Chart

Additional supplementary data from the comprehensive berberine autoimmune hepatitis study, further supporting the connection between gut microbiota modulation and liver inflammation resolution.

Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut …

Figure 2
Figure 2 Chart

Clinical outcome data from a trial comparing acacia fiber and probiotic Bifidobacterium lactis (Bla80) supplementation for relieving gastrointestinal complaints in adult participants.

Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with …

acacia fiber (AF) (n=55) and probiotic Bifidobacterium Lactis (Bla80) (n=57) treatment. Linear mixed model analysis showed that Acacia fiber and Probiotic Bla80 significantly increased stool frequency compared to placebo (P<0.001 and P=0.02) for Acacia
Figure 3 Chart

Stool mass measurements before and after intervention with acacia fiber or probiotic Bifidobacterium lactis (Bla80) for gastrointestinal complaints, comparing changes between treatment groups.

Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with …

terium Lactis (Bla80) (n 57), and Stool mass (B) before (WK4) and after (WK8) for placebo (n 55), prebiotic acacia fiber (AF) (n 54) and probiotic Bifidobacterium Lactis (Bla80) (n 57) treatment
Figure 4 Chart

Stool mass measurements before and after intervention with acacia fiber or probiotic Bifidobacterium lactis (Bla80) for gastrointestinal complaints, comparing changes between treatment groups.

Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with …

rium Lactis (BLa80) (n=57) treatment. The vertical dashed line indicates the start of the intervention period (day 28). Linear mixed model analysis showed a significant decrease in IBS-SSS for probiotic BLa80 during the intervention period (P=0.03)
Figure 5 Chart

Longitudinal gastrointestinal symptom tracking during the acacia fiber and probiotic Bifidobacterium lactis intervention trial, with the vertical dashed line marking the transition from baseline to active treatment.

Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with …

1–28) and intervention period (day 29–56) for placebo (n=57), prebiotic acacia fiber (AF) (n=55) and probiotic Bifidobacterium Lactis (Bla80) (n=57) treatment
Figure 6 Chart

Daily symptom data spanning the run-in period (days 1-28) and intervention period (days 29-56) for placebo, prebiotic acacia fiber, and probiotic Bifidobacterium lactis groups in the gastrointestinal complaint trial.

Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with …

Figure 4
Figure 4 Chart

Gut microbiota diversity analysis from pregnant women receiving probiotic supplementation, assessing changes in microbial community composition and functional capacity.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 5
Figure 5 Chart

Gut microbiota diversity analysis from pregnant women receiving probiotic supplementation, assessing changes in microbial community composition and functional capacity.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 6
Figure 6 Chart

Extended microbiome analysis data from the pregnancy probiotic trial, examining functional diversity shifts in the gut microbiota of mothers and their offspring.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 7
Figure 7 Chart

Extended microbiome analysis data from the pregnancy probiotic trial, examining functional diversity shifts in the gut microbiota of mothers and their offspring.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 8
Figure 8 Chart

Extended microbiome analysis data from the pregnancy probiotic trial, examining functional diversity shifts in the gut microbiota of mothers and their offspring.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 9
Figure 9 Chart

Extended microbiome analysis data from the pregnancy probiotic trial, examining functional diversity shifts in the gut microbiota of mothers and their offspring.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 10
Figure 10 Chart

Extended microbiome analysis data from the pregnancy probiotic trial, examining functional diversity shifts in the gut microbiota of mothers and their offspring.

Effect of probiotic administration during pregnancy on the functional diversity of the …

Figure 1 : The screening and treatment algorithm for patients with IBD regarding bone health. This algorithm summarises and simplifies the above screening recommendations and is intended as a practical aid.
Figure 2

Figure 1 : The screening and treatment algorithm for patients with IBD regarding bone health. This algorithm summarises and simplifies the above screening recommendations and is intended as a practical …

Bone health in patients with inflammatory bowel disease.

Figure 1. Effects of C. butyricum and 25-hydroxyvitamin D3 on the latency-to-lie time, tibial content of calcium and phosphorus, BMD and bone-breaking strengthen of broilers. (A) LTL. (B) calcium. (C) phosphorus. (D) BMD. (E) bone-breaking strengthen. (F)
Figure 1 Chart

Effects of dietary Clostridium butyricum and 25-hydroxyvitamin D3 supplementation on latency-to-lie time in a poultry model, indicating improvements in leg health and bone strength.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 2
Figure 2 Chart

Experimental data from a study on dietary Clostridium butyricum and 25-hydroxyvitamin D3 and their combined effects on bone metabolism through gut microbiota modulation in poultry.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 4. Effects of Clostridium butyricum and 25-hydroxyvitamin D3 on the hypothalamic and intestinal brain-gut peptides in broilers. (A) Caecal 5-HT content. (B) Caecal DA content. (C) Caecal GLP-1 content. (D) Ileal PYY content. (E) Hypothalamic 5-HT c
Figure 3 Chart

Hypothalamic signaling pathway analysis in poultry fed Clostridium butyricum and 25-hydroxyvitamin D3, examining effects on bone metabolism regulatory mechanisms.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 5. Effects of Clostridium butyricum and 25-hydroxyvitamin D3 on caecal SCFAs in broilers. (A) acetic acid level. (B) propionic acid level. (C) isobutyric level. (D) butyric level. (E) isovaleric level. (F) valeric level. Con birds fed basal diet wi
Figure 4 Chart

Caecal short-chain fatty acid (SCFA) concentrations in poultry supplemented with Clostridium butyricum and 25-hydroxyvitamin D3, linking gut fermentation products to bone metabolism modulation.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Pagina 16 di 20